Resonant Capital Advisors LLC Has $260,000 Holdings in Novartis AG (NYSE:NVS)

Resonant Capital Advisors LLC raised its holdings in Novartis AG (NYSE:NVS) by 6.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,676 shares of the company’s stock after buying an additional 162 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Novartis were worth $260,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Union Bancaire Privee UBP SA acquired a new position in Novartis in the fourth quarter valued at approximately $27,000. Legacy Investment Solutions LLC acquired a new position in shares of Novartis during the third quarter worth approximately $28,000. Fortitude Family Office LLC raised its position in shares of Novartis by 503.8% during the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after purchasing an additional 267 shares during the period. Clean Yield Group acquired a new position in shares of Novartis during the third quarter worth approximately $43,000. Finally, Brooklyn Investment Group acquired a new position in shares of Novartis during the fourth quarter worth approximately $55,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVS. BMO Capital Markets upped their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com lowered Novartis from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Stock Up 0.8 %

Shares of NYSE:NVS opened at $105.54 on Tuesday. The company has a market capitalization of $215.72 billion, a PE ratio of 17.95, a price-to-earnings-growth ratio of 1.51 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The business has a fifty day moving average price of $100.10 and a two-hundred day moving average price of $108.43. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.79% and a net margin of 23.56%. Analysts forecast that Novartis AG will post 8.34 earnings per share for the current year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.